Predictive power. Multiplate analyzer
|
|
- Theodore Porter
- 8 years ago
- Views:
Transcription
1 Predictive power Multiplate analyzer
2 Multiplate analyzer Strengthening Roche s hemostasis portfolio With a series of industry firsts and innovative applications for early disease detection and monitoring, Roche is introducing yet another novel product to its hemostasis portfolio. Whilst Roche`s responsive laboratory coagulation roadmap is going to deliver platforms with outstanding productivity, the Multiplate system focuses on addressing a significant unmet medical need. Improving the assessment of a patient s platelet function status is key for hematologists, cardiologists and anesthetists in order to support clinical decisions in cardiology, surgery and intensive care. With the acquisition of Verum Diagnostica GmbH Roche gains an innovative and unique platelet function testing solution. Carried by a strong medical momentum its best in class predictivity of thrombotic and bleeding risk allows to tailor anti-platelet therapy and stratify patients at risk for bleeding. Supported by a highly standardized testing technology the Multiplate system has the potential to set new standards in patient care. Therefore Multiplate is a perfect complement to Roche`s ambition to combine true innovation with proven medical and diagnostic expertise into a new hemostasis portfolio.
3 Predictive power Multiplate analyzer Medical momentum > 200 Medline-listed publications with Multiplate Consensus paper of Working Group on High-On-Treatment-Platelet-Reactivity featuring Multiplate Guidelines introducing recommendations for platelet function testing in CABG and PCI for patients treated with clopidogrel Best predictivity for tailored anti-platelet therapy Approx. 20% of patients do not respond adequately to clopidogrel Other potent drugs have been introduced, which have advantages and disadvantages compared to clopidogrel and which are up to fold more expensive compared to clopidogrel Patients showing a low-response to clopidogrel in Multiplate analysis have shown a 5-10 fold risk for ischemic complications Patients with a high response to clopidogrel have shown a 2.6 fold risk for major bleeding Successful experiences using the tailoring of anti-platelet therapy aided by Multiplate analysis have been reported by several groups Consistent results Standardised and fast test procedure utilizing whole blood, easy to use, low blood volume/test Broad menu of CE marked tests for various applications 5 channel analyzer with high throughput High sensitivity and dynamic range Twin sensors for quality control Best predictivity for stratification of bleeding risk Patients with impaired platelet function according to Multiplate analysis have an increased risk for intra- and postoperative bleeding complications and/or transfusion requirements Multiplate can contribute to an improved management of bleeding complications in surgical procedures
4 Platelet function testing Overview Blood platelets play a pivotal role in physiological hemostasis, but also in the development of arterial thrombosis (myocardial infarction and stroke). Platelet function testing is utilized in the analysis of inherited and acquired platelet function disorders, in the analysis of platelet function in anesthesia and intensive care, and for monitoring of platelet function antagonists. Analysis of platelet disorders Various drugs and diseases, as well as genetic factors can lead to platelet dysfunction, which may cause a transient or permanent bleeding tendency. The Multiplate analyzer can detect platelet dysfunction and thus aid in the therapeutic management of such patients. Platelet function in anesthesia and intensive care Platelet dysfunction can lead to severe bleeding complications. The detection or exclusion of platelet dysfunction before invasive procedures or in bleeding patients can support the risk stratification and management in these situations. Monitoring of anti-platelet therapy Anti-platelet drugs are among the most frequently administered drugs in modern medicine. A combination of aspirin with an ADP receptor antagonist (clopidogrel, prasugrel or ticagrelor) is the mainstay antiplatelet therapy for patients with acute coronary syndromes (ACS) and/or coronary interventions with stent placement. The challenge of compliance and low response In the increasingly elderly and multimorbid patient population the issue of adherence to prescribed medications is of crucial importance. Through the ability to monitor and thus control anti-platelet therapy the Multiplate system can support the management of these patients. In addition anti-platelet drugs do not always act properly, even when taken appropriately by the patient. Reduced absorption, as frequently witnessed in patients suffering from cardiac shock, as well as an impaired metabolisation of the drug (especially clopidogrel) due to genetic factors, comedications or other confounders can lead to a diminished anti-platelet response to the medication ( low response ). In large prospective evaluations it was shown with Multiplate results that up to 20% of patients do not respond adequately to clopidogrel treatment. These patients have a 5-10 fold increased risk for stent thrombosis, stroke and q-wave myocardial infarction 1-4 following percutaneous coronary interventions (PCI). Novel ADP P2Y12 receptor antagonists Prasugrel and ticagrelor are novel P2Y12 receptor antagonists that act more potently and more consistently than clopidogrel. This includes an enhanced risk of fatal bleedings (prasugrel) and higher risk for non-cabg related major bleedings and dyspnea (ticagrelor). 5,6 At the expense of a higher rate of bleeding or undesired side effects not all patients are likely to benefit from the use of these drugs compared to the standard therapy with clopidogrel. In addition prasugrel and ticagrelor are up to times more expensive than clopidogrel. 7 In summary, the question of which ADP receptor inhibitor to use has pharmacological as well as socio-economic implications with advantages and disadvantages for all three available drugs.
5 Best predictivity for tailored anti-platelet therapy Adequate platelet inhibition is of pivotal importance for the clinical management of patients at high risk of arterial thrombosis, e.g. after stent placement or in acute coronary syndrome (ACS). Clopidogrel or Aspirin low-response (reduced effect of the prescribed drug in the patient) is associated with a significantly increased risk of arterial thromboembolism. Clopidogrel low-response is found in approximately 20% of patients. The Multiplate system is highly sensitive for the detection of response to Aspirin, clopidogrel, prasugrel, IIbIIIa receptor antagonists and other platelet inhibitors. Multiple prospective studies have shown the Multiplate analysis best predicitivity to determine patients at risk of atherothrombotic events: A large (n=1608) prospective study evaluating the clinical impact of clopidogrel reponse in the setting of PCI has shown that clopidogrel low-responders exhibited a 9.4 fold increased risk of early stent thrombosis 1 whereas a regular responders risk of stent thrombosis was very low (0,2%) The Multiplate system better predicts stent thrombosis compared to the flow cytometric VASP assay, 4 and stent thrombosis compared to genetic testing of polymorphisms of CYP2C19 gene alleles 8 The prognostic value of Multiplate analysis was also demonstrated in neuroradiology 9 In a consensus publication the Multiplate test is listed with unmatched odds ratios to determine risk enhancement in clopidogrel low responders 10 Multiplate analysis is predictive for both thrombotic and bleeding risk after PCI 11 Evidence is available confirming that low-response to clopidogrel is a modifiable risk factor and Multiplate guided antiplatelet therapy has the potential to improve patient outcome: Routine PF testing [with Multiplate ] is useful for guidance of tailored antiplatelet treatment and switching to prasugrel markedly reduces stent thrombosis risk in high platelet reactivity patients on clopidogrel. 12 Routine tailoring of antiplatelet therapy with MEA [Multiplate ] is capable of eradicating early definite stent thrombosis 13 tailoring the dose of clopidogrel with the Multiplate analyzer significantly reduced the risk of ischemic complications as compared to a uniform dosing strategy of 75 mg clopidogrel in an all-comer cohort of patients after PCI. 14 Recent PCI guidelines are supporting PFT with a class IIb recommendation: In patients treated with clopidogrel with high platelet reactivity, alternative agents, such as prasugrel or ticagrelor, might be considered (Level of evidence: C) 15
6 Best predictivity for stratification of bleeding risk Blood platelet function plays a pivotal role in hemostasis during surgery and following traumatic injuries. Platelet dysfunction can lead to bleeding complications, increased transfusion of blood products and occasionally the need for surgical re-exploration. Therefore, in patients undergoing surgery the ability to assess platelet function before, during and after the intervention is desirable. Causes of platelet dysfunction Platelet dysfunction may be caused by the ingestion or administration of anti-platelet drugs, concomitant medications such as antibiotics or anti-rheumatics, or by patient comorbidities. Stratification of bleeding risk Several studies have shown the ability of the Multiplate analyzer to detect patients with an increased risk for bleeding complications and/or transfusion requirements during surgery Testing the effects of anti-platelet drugs Aspirin and ADP receptor antagonists can be sensitively assessed using the Multiplate analyzer. Patients undergoing cardiac surgery who demonstrate a strong anti-platelet effect of clopidogrel have a significantly higher risk to experience major bleeding compared to individuals who express a weak or lack of anti-platelet effect. 16 Several studies have shown that Multiplate analysis can effectively determine the recovery from the effects of anti-platelet drugs such as aspirin 21,22 clopidogrel and prasugrel. 23 Reduced need for preoperative waiting periods Clopidogrel should normally be discontinued for 5 days before a surgical procedure.. According to the 2011 blood conservation clinical practice guidelines platelet function testing may be used to detect clopidogrel non-responders who may not require a preoperative waiting period after clopidogrel discontinuation. 24 This can lead to reduced hospitalization times and considerable cost savings. Citations from studies using the Multiplate analyzer: The multiple electrode aggregometry ADP test in patients under thienopyridine treatment and undergoing cardiac surgery is associated with postoperative bleeding and platelet transfusion and provides an accurate preoperative prediction of postoperative bleeding risk. Ranucci et al. Ann Thorac Surg 2011;91: The inclusion of MEA in our POC supported algorithm allowed for timely and specific detection of platelet dysfunction. Goerlinger K et al. Anesthesiology Dec;115(6): POC-guided therapy was associated with lower Fresh Frozen Plasma and Platelet Concentrates usage and costs as well as an improved clinical outcome in this prospective randomized single-center study. Weber CF et al. Anesthesiology in press
7 Consistent results The Multiplate analyzer is an easy to use, compact system. It deploys a Windows based interface programmed with a comprehensive menu of whole blood platelet function assays. Its flexible design allows for a fast turn around time of 10 minutes per test a period. Combined with its 5 channels, this permits the processing of up to 30 tests per hour that require only 300 µl blood per analysis. Broad menu of tests for a wide spectrum of applications With its menu of six CE marked procedures (ADPtest, ASPItest, TRAPtest, COLtest, RISTOtest, ADPtest HS) the Multiplate system is sensitive for the monitoring of platelet function inhibitors determines platelet dysfunction before invasive procedures and in bleeding patients is suitable for the detection of hereditary or acquired platelet function disorders 25 is sensitive for von Willebrand Disease (comparable to optical aggregometry) 26 is used in various research models, the functional determination of Heparin induced thrombocytopenia in whole blood and various animal models Patented Detection Technology The signal reaction in the Multiplate analyzer is triggered by the adhesion of activated platelets to the surfaces of the sensor electrodes that induces an increase of electrical resistance. Each test cell incorporates two pairs of sensors (multiple electrode aggregometry = MEA), serving as a built-in quality control. Citations from studies using the Multiplate analyzer: MEA is a fast and standardized method to individually assess platelet function prior to and after clopidogrel treatment. Sibbing D et al. Thromb Haemost 2008; 99: As a whole blood method, Multiplate avoids the handling of blood samples, with the advantage that the cellular environment remains unchanged, and allows rapid evaluation of platelet aggregation by ready-to-use test cuvettes with 2 independent sensor units. In addition, the use of whole blood tests platelet function under more physiologic conditions. Paniccia R et al. Am J Clin Pathol Jun;131(6): The effect size by use of multiple electrode aggregometry (MEA) was consistently greater for clopidogrel and aspirin as compared to other methods. Siller-Matula JM et al. Thromb Haemost Aug;102(2): MEA accurately detected the time-dependent antiplatelet effect of aspirin and provided reproducible platelet aggregation results. Jambor C et al. Anesth Analg 2009;109: A further advantage of this method [Multiplate ] allows the clinician to use small amounts of whole blood. Halimeh S et al. Klin Padiatr 222(3), 2010;
8 Medical momentum With its introduction to the market in 2005, the Multiplate analyzer has witnessed great momentum in terms of adoption and medical consensus on its value. Since that time over 200 medline listed publications have been generated with the Multiplate system, validating the growing interest and adoption of the Multiplate analyzer in clinical practice. The MEA principle of the Multiplate analyzer has been incorporated into the 2008 revision of the Clinical and Laboratory Standards Institute (CLSI) approved guideline on platelet function testing. 36 Large prospective studies such as that performed by the ISAR group in a cohort of 1608 patients associated Multiplate results with risk for stent thrombosis and other ischemic events in PCI patients. 1 The JACC consensus paper of the high on treatment platelet reactivity working group made reference to the Multiplate analyzer with unmatched odds ratios to determine patients at enhanced thrombotic risk. 10 Platelet function testing is further supported by guidelines. The 2011 American College of Cardiology Foundation/American Heart Association/Society for Cardiovascular Angiography and Interventions Guideline for Percutaneous Coronary Intervention 15 includes platelet function testing for anti-platelet drug selection with a class IIb recommendation: Platelet function testing may be considered in patients at high risk for poor clinical outcomes. (Level of Evidence: C). In patients treated with clopidogrel with high platelet reactivity, alternative agents, such as prasugrel or ticagrelor, might be considered. (Level of Evidence: C) Platelet function testing has also received a Class IIb recommendation by the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists in their 2011 blood conservation clinical practice guidelines. 24 Point-of-care testing for platelet ADP responsiveness might be reasonable to identify clopidogrel nonresponders who are candidates for early operative coronary revascularization and who may not require a preoperative waiting period after clopidogrel discontinuation. (Level of evidence C). As more evidence is gathered to demonstrate the benefits of anti-platelet therapy aided by the use of the Multiplate analyzer, there is further room for guidelines recommendations to become stronger.
9 Multiplate analyzer Strengthening Roche s hemostasis portfolio Platelet function testing Extended routine testing Multiplate analyzer cobas t 411 coagulation analyzer cobas t 611 coagulation analyzer Patient and professional monitoring cobas IT applications Routine and special testing CoaguChek XS system CoaguChek XS Plus system CoaguChek XS Pro system Next generation coagulation analyzers Laboratory automation cobas p 612 pre-analytical system MODULAR PRE-ANALYTICS EVO
10 References 1 Sibbing, D., Braun, S., Morath, T., Mehilli, J., Vogt, W., Schömig, A., Kastrati, A., von Beckerath, N. (2009). Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. Mar 10;53(10): Sibbing, D. et al. (2010). Clopidogrel response status assessed with Multiplate point-ofcare analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost. Jan;103(1): Schulz, S. et al. (2010). Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. Am Heart J. Aug;160(2): Siller-Matula, J.M. et al. (2010). Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost. Feb;8(2): Wiviott, S.D. et al. (2007). N Engl J Med; 357: Wallentin, L. et al. (2009). N Engl J Med; 361: NHS - New drug evaluation: No 109, 01 (2011). Regional Drug and Therapeutics Centre, 8 Siller-Matula, J.M. et al. (2012). Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost. Apr;10(4): Müller-Schunk, S. et al. (2008). Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting. Am J Neuroradiol.; 29(4): Bonello, L. et al. (2010). Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol Sep 14;56(12): Sibbing, D. et al. (2010). Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol. Jul 20;56(4): Sibbing, D. et al. (2012). J Am Coll Cardiol;59;E Christ, G. et al. (2011). Eurointervention; Vol 7;Suppl M. 14 Hazarbasanov, D. et al. (2012). Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. J Thromb Thrombolysis. Jan 15. [Epub ahead of print]. 15 Levine, G.N. et al. (2011). ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. Dec 6;124(23): Ranucci, M. et al. (2011). Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg. Jan;91(1): Wang, H., Leff, J., Nair, S., Shore-Lesserson, L. (2012). Use of multiple electrode aggregometry (MEA) in predicting postoperative bleeding and transfusion requirements after cardiopulmonary bypass surgery, a prospective observational study. Anesth Analg;114(suppl); Reece, M.J. et al. (2011). Near-patient platelet function testing in patients undergoing coronary artery surgery: a pilot study. Anaesthesia. Feb;66(2): Rahe-Meyer, N. et al. (2008). An evaluation of cyclooxygenase-1 inhibition before coronary artery surgery: aggregometry versus patient self-reporting. Anesth Analg. Dec;107(6): Rahe-Meyer, N. et al. (2009). Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry. Acta Anaesthesiol Scand. Feb;53(2): Jámbor, C. et al. (2009). Whole blood multiple electrode aggregometry is a reliable point-of-care test of aspirin-induced platelet dysfunction. Anesth Analg.;109(1): Jámbor, C. et al. (2011). Multiple electrode whole blood aggregometry, PFA-100, and in vivo bleeding time for the point-of-care assessment of aspirin-induced platelet dysfunction in the preoperative setting. Anesth Analg. Jul;113(1): Bernlochner, I. et al. (2012). A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel. Platelets. Feb Ferraris, V.A. et al. (2011). update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. Mar;91(3): Awidi, A. et al. (2009). Comparison of platelet aggregation using light transmission and multiple electrode aggregometry in Glanzmann thrombasthenia. Platelets. Aug;20(5): Valarche, V. et al. (2011). Multiplate whole blood impedance aggregometry: a new tool for von Willebrand disease. J Thromb Haemost. Aug;9(8): Ferrer-Marin, F. et al. (2011). Effects of in vitro adult platelet transfusions on neonatal hemostasis. J Thromb Haemost. May;9(5): Sibbing, D. et al. (2010). Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. Feb 2;121(4): Morel-Kopp, M.C. et al. (2012). Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study. Thromb Haemost. Mar;107(3): Elalamy, I. et al. (2009). Heparin-induced multiple electrode aggregometry: a potential tool for improvement of heparin-induced thrombocytopenia diagnosis. J Thromb Haemost. Nov;7(11): Kalbantner, K. et al. (2010). Measurement of platelet function in dogs using a novel impedance aggregometer. Vet J. Aug;185(2): Baumgarten, A. et al. (2010). Measurement of platelet aggregation in ovine blood using a new impedance aggregometer. Vet Clin Pathol. Jun;39(2): Czura, C.J. et al.(2010). Vagus nerve stimulation regulates hemostasis in swine. Shock. Jun;33(6): Kirkeby, A. et al. (2008). High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO). Thromb Haemost. Apr;99(4): Fröbert, O. et al. (2010). Platelet function in brown bear (Ursus arctos) compared to man. Thromb J. Jun 2;8: Clinical and Laboratory Standards Institute (CLSI) document H58-A. (2008). Platelet Function Testing by Aggregometry; Approved Guideline. ISBN
11
12 Roche Diagnostics International Ltd CH-6343 Rotkreuz Switzerland 2012 Roche All trademarks mentioned enjoy legal protection.
Platelet Function analysis using Multiple Electrode Aggregometry (Multiplate )
Platelet Function analysis using Multiple Electrode Aggregometry (Multiplate ) Multiplate platelet function analysis in whole blood based on impedance aggregometry Multiplate instrument 5 channels for
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationPlatelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D.
Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel Kiyuk Chang, M.D., Ph.D. Cardiovascular Center & Cardiology Division Seoul St. Mary s Hospital The Catholic University
More informationANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION
More informationAntiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
More informationDUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
More informationABSTRACT INTRODUCTION EKATERINA LENK, MICHAEL SPANNAGL PLATELET FUNCTION TESTING-GUIDED ANTIPLATELET THERAPY. Ekaterina Lenk 1, Michael Spannagl 2 1
Copyright 2013 International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). All rights reserved EKATERINA LENK, MICHAEL SPANNAGL The Journal of the International Federation of Clinical
More informationObjectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
More informationDual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationMultiplateT Analyzer für die Thrombozytenfunktionstestung. Literaturübersicht
MultiplateT Analyzer für die Thrombozytenfunktionstestung Literaturübersicht MultiplateT Analyzer Stärkung des Hämostaseportfolios Die Gerinnungsdiagnostik gehört fur Roche Diagnostics zu den wichtigsten
More informationGUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY
BLOOD CONSERVATION STRATEGIES IN CARDIAC SURGERY: MORE IS BETTER GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY DIMITRIOS V. AVGERINOS MD, PhD, FACS, FACC Department of Cardiac Surgery,
More information510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY A. 510(k) Number: k103555 B. Purpose for Submission: New submission C. Measurand: Platelet aggregation D. Type of Test: Platelet aggregometer
More informationA Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs
A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory
More informationMultiplate platelet function analysis - application and interpretation
Dr. Andreas Calatzis PD Dr. Michael Spannagl Department for Haemostasis and Transfusion Medicine Munich University Clinic Ludwig-Maximilians University Ziemssen Str. 1 80336 Munich, Germany calatzis@haemostasis.de
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationGetting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot
Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:
More informationRivaroxaban for acute coronary syndromes
Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following
More informationABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
More informationIs There A LIfe for DES after discontinuation of Clopidogrel
Chicago 2014 Is There A LIfe for DES after discontinuation of Clopidogrel Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin:
More informationprodigy study: duration of dual antiplatelet therapy under review In BrIef In Brief NPS RADAR AuguSt 2012
3 In BrIef A digest of news items about NPS RADAR, new drugs and changes to PBS listings prodigy study: duration of dual antiplatelet therapy under review Dual antiplatelet therapy with aspirin and clopidogrel
More informationAntiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015
Heartline 2015 Genova 13 14 Novembre 2015 STEMI : cosa c è di nuovo? Antiaggreganti Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia STEMI : cosa c è di nuovo?
More informationPerspectives on the Selection and Duration of Dual Antiplatelet Therapy
Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University
More informationEuropean Commission Approves EFIENT (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationL'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy ISO 9001
L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Scientific Advances and Cardiovascular Mortality Nabel and
More informationComo mejorar el manejo médico de los diabéticos con SCA
DIABETES Y ENFERMEDAD CORONARIA EN 2011 Como mejorar el manejo médico de los diabéticos con SCA Antonio Fernández-Ortiz Jueves, 20 Octubre 2011 INSTITUTO CARDIOVASCULAR Conflicto de interés: Antonio Fernández-Ortiz
More informationCilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
More informationManagement of the new antiplatelets and anticoagulants
Management of the new antiplatelets and anticoagulants Session No.: 1 Name: C. Boustiere, T Ponchon Guidelines : Anti-thrombotic agents and digestive endoscopy 2006 : French guideline (SFED) 2007 : Japanese
More informationTHE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS
THE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS Ingo Ahrens, Christoph Bode Cardiology and Angiology I, Heart Center Freiburg University, Freiburg,
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationNew Approaches to, and Indications for, Antiplatelet Therapy
New Approaches to, and Indications for, Antiplatelet Therapy Kenneth A. Bauer, MD Professor of Medicine, Harvard Medical School Chief, Hematology Section, VA Boston Healthcare System Director, Thrombosis
More informationThe Anti coagulated Patient: The Cardiologist s View. February 28, 2015
The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS
More informationTranexamic Acid. Tranexamic Acid. Overview. Blood Conservation Strategies. Blood Conservation Strategies. Blood Conservation Strategies
Overview Where We Use It And Why Andreas Antoniou, M.D., M.Sc. Department of Anesthesia and Perioperative Medicine University of Western Ontario November 14 th, 2009 Hemostasis Fibrinolysis Aprotinin and
More informationACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline
ACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline David Zhao, MD, FACC, FSCAI Professor of Medicine and Cardiac Surgery Harry and Shelley Page Professor in Interventional Cardiology
More informationWOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of
More informationThe Society of Thoracic Surgeons (STS) Workforce on
FROM STS WORKFORCE ON EVIDENCE BASED SURGERY 2012 Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations* Victor A. Ferraris,
More informationBayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
More informationNew oral anticoagulants and antiplatelets: Where do they fit? Meredith Hollinger, PharmD BCPS
New oral anticoagulants and antiplatelets: Where do they fit? Meredith Hollinger, PharmD BCPS Clinical Pharmacy Specialist, Cardiology September 2012 Objectives Describe the mechanisms of action for novel
More informationUniversity of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial
Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationDATE: 29 August 2012 CONTEXT AND POLICY ISSUES
TITLE: Dual Antiplatelet Therapy and Enoxaparin or Unfractionated Heparin for patients with ST-elevation Myocardial Infarction: A Review of the Clinical Evidence DATE: 29 August 2012 CONTEXT AND POLICY
More informationMarco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo
Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo Acute Coronary Syndromes: oral antithrombotic therapy Focus on
More informationrivaroxaban 2.5mg film-coated tablets (Xarelto ) SMC No. (1062/15) Bayer plc.
rivaroxaban 2.5mg film-coated tablets (Xarelto ) SMC No. (1062/15) Bayer plc. 05 June 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationNone. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
More informationIssues and Challenges in ACS Management. Dr.Nakul Sinha MD.DM, FACC. Sahara Hospital, LUCKNOW
1 Issues and Challenges in ACS Management Dr.Nakul Sinha MD.DM, FACC. Sahara Hospital, LUCKNOW 2 Disclaimer Presentation are intended for educational purposes only and do not replace independent professional
More informationOptimal Duration of Dual Antiplatelet Therapy
Optimal Duration of Dual Antiplatelet Therapy Luis A Guzman, MD, FACC, FSCAI Associate Professor of Medicine Director, Cardiac and Vascular Cath Lab University of Florida College of Medicine - Jacksonville
More information1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
More informationMANAGEMENT AKUTES KORONARSYNDROM: RISIKOSTRATIFIZIERUNG UND THERAPIE. Peter Wenaweser Universitätsklinik für Kardiologie
MANAGEMENT AKUTES KORONARSYNDROM: RISIKOSTRATIFIZIERUNG UND THERAPIE Peter Wenaweser Universitätsklinik für Kardiologie Scientific Advances & Cardiovascular Mortality 1950 to 2010 Nabel EM and Braunwald
More informationBayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationPerioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time
Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time Robert Chilton DO, FACOI, FACC, FAHA Professor of Medicine University of Texas Health Science Center Director
More informationR EFERENCES. Summary and conclusions
R EFERENCES Summary and conclusions 129 S UMMARY AND CONCLUSIONS SUMMARY AND GENERAL DISCUSSION 130 Constant vasodilatation, inhibition of platelet and monocyte adhesion, and local thrombolysis are the
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSurgery and Anti-Coagulation Agents
CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Pre-admission clinics and surgical wards Personnel involved in surgical pre-assessment
More informationUse of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia
Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Insertion, removal or presence of a catheter in selected sites can place a patient who is antithrombotic agent at risk for a local bleeding
More informationBayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban
More informationTriple thérapie anti-thrombotique chez le coronarien. Y Cottin Dijon
Triple thérapie anti-thrombotique chez le coronarien Y Cottin Dijon «Dans la vie, rien n est à craindre, tout est à comprendre» Marie Curie Epidémiologie Aspirine/Clopidogrel/Ticagrelor/Prasugrel Durée?
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationNnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
More informationNew anticoagulants: Monitoring or not Monitoring? Not Monitoring
The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and
More informationAntiplatelet therapy:
Balanced information for better care Antiplatelet therapy: Aggregating the latest evidence Evaluating the choices for a preventive therapy with impressive benefits and important risks Antiplatelet agents
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationReview Article Type 2 Diabetes and ADP Receptor Blocker Therapy
Diabetes Research Volume 2016, Article ID 6760710, 7 pages http://dx.doi.org/10.1155/2016/6760710 Review Article Type 2 Diabetes and ADP Receptor Blocker Therapy Matej Samoš, 1 Marián Fedor, 2 František
More informationImplementation of Pharmacogenomics in Clinical Practice: Barriers and Potential Solutions
Molecular Pathology : Principles in Clinical Practice Implementation of Pharmacogenomics in Clinical Practice: Barriers and Potential Solutions KT Jerry Yeo, Ph.D. University of Chicago Email: jyeo@bsd.uchicago.edu
More informationThrombosis and Bleeding
Many questions, few answers Thrombosis and Bleeding Pierre Noel MD Mayo Arizona Scope of the Problem Thrombosis PV 12-39% ET 11-25% MF 10% 60-70% of thrombosis are arterial Splanchnic and cerebral thrombosis
More informationChristopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona
Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Areas to be covered Historical, current, and future treatments for various cardiovascular disease: Atherosclerosis (Coronary
More informationManaging Anticoagulation for Atrial Fibrillation 2015
Managing Anticoagulation for Atrial Fibrillation 2015 Vikranth Gongidi, DO FACC FACOI Indian River Medical Center Vero Beach, FL Atrial Fibrillation Background and Guidelines Decisions to anticoagulate
More informationIntroduction. Background to this event. Raising awareness 09/11/2015
Introduction Primary Care Medicines Governance HSCB Background to this event New class of medicines Availability of training Increasing volume of prescriptions Reports of medication incidents Raising awareness
More informationNew Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Late-Breaking Science at ESC Congress 2015: New Real-World Evidence Reaffirms
More informationUSE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals:
More informationJournal of the American College of Cardiology Vol. 55, No. 16, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.
Journal of the American College of Cardiology Vol. 55, No. 16, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.11.080
More informationCARDIAC RISKS OF NON CARDIAC SURGERY
CARDIAC RISKS OF NON CARDIAC SURGERY N E W S T U D I E S & N E W G U I D E L I N E S W. B. C A L H O U N, M D, F A C C 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management
More informationECG may be indicated for patients with cardiovascular risk factors
eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationDuration of Dual Antiplatelet Therapy after Coronary Stent Placement: How long is too long?
Duration of Dual Antiplatelet Therapy after Coronary Stent Placement: How long is too long? Image: http://kids.britannica.com/comptons/art-165917/the-insertion-of-a-stent-into-a-coronary-artery-where October
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationAnnals of West University of Timisoara
Annals of West University of Timisoara Series of Chemistry 20 (1) (2011) 47-58 LABORATORY TESTING OF PLATELET FUNCTION BY AGGREGOMETRY: WHAT TEST SHOULD BE USED? Daniela Maximov a, Alina Lupu a, Cristiana
More informationPerioperative Cardiac Evaluation
Perioperative Cardiac Evaluation Caroline McKillop Advisor: Dr. Tam Psenka 10-3-2007 Importance of Cardiac Guidelines -Used multiple times every day -Patient Safety -Part of Surgical Care Improvement Project
More informationHot Line Session at European Society of Cardiology (ESC) Congress 2014:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily
More informationProstate Assessment Pathway Prostate Biopsy Alerts
Prostate Assessment Pathway Prostate Biopsy Alerts Guidelines for the Management of Patient Preparation, Medications and Complications July 2015 Table of Contents Roles and Responsibilities. 1 SECTION
More information9/5/14. Objectives. Atrial Fibrillation (AF)
Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three
More informationCardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease
Cardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease What is Cardiac Rehabilitation? Cardiac rehabilitation is a comprehensive exercise, education, and behavior modification
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012
More informationIl punto sulla terapia antitrombotica nelle sindromi coronariche acute
Santa Margherita Ligure TIGULLIO CARDIOLOGIA 2012 16-17 Febbrajo 2012 Il trattamento dell infarto miocardico acuto ad ST spraslivellato: dal territorio al laboratorio di emodinamica Il punto sulla terapia
More informationThrombophilia. Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003
Thrombophilia Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003 Thrombophilia Hereditary and acquired risk factors for thrombosis Venous thromboembolism Arterial thromboembolism
More informationAntithrombotic therapy
Orthogeriatrics Clinical Summary Document Antithrombotic therapy Topics Preexisting anticoagulation and timing of surgery Reversal of anticoagulation Perioperative thromboprophylaxis When should we be
More information510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE AND INSTRUMENT TEMPLATE
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE AND INSTRUMENT TEMPLATE A. 510(k) Number: K041502 B. Purpose for Submission: To change the name of a previously cleared analyzer, and
More informationDescription of problem Description of proposed amendment Justification for amendment ERG response
KEY INACCURACIES Issue 1 Distinguishing between groups of STEMI patients Key issue throughout the report The ERG distinguishes between groups of STEMI patients defining four patient groups: STEMI without
More informationΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν
ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν The AF epidemic Mayo Clinic data (assuming a continued increase in the AF incidence) Mayo
More informationLow Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice
Low Molecular Weight Heparin All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Starting Point Low Molecular Weight Heparin (LMWH): Inhibits factor Xa and factor IIa (thrombin) Small
More informationEndoscopy & ACS. 8/1/2014 Dr. Whang
Endoscopy & ACS 8/1/2014 Dr. Whang Outline I. Antiplatelets II. Coronary Artery Disease in U.S. III. GI Bleeding in ACS IV. ACC/AHA guidelines: Dual Antiplatelet Therapy in CAD V. PPI and Plavix Controversy
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 06/06/2012 Review Date 06/06/2014 Version 1.1 EQIA Yes /
More informationWOEST. NOAC, OAC and PCI: An update ' W.Dewilde, MD,PhD. Amphia Hospital, Breda, The Netherlands
NOAC, OAC and PCI: An update ' W.Dewilde, MD,PhD Amphia Hospital, Breda, The Netherlands DRES, Hart van Nijkerk, June 2015 Disclosure belangen spreker (potentiële) belangenverstrengeling Voor bijeenkomst
More informationBlood Management Today Incorporating TEG
Blood Management Today Incorporating TEG AMSECT NABM meeting Mike Miller Manager Clinical Manager Hemostasis Training Haemonitics Rx Only 2011 Haemonetics Corporation. Haemonetics, TEG, RapidTEG and Thrombelastograph
More informationRational for secondary prophylaxis in VWD
Rational for secondary prophylaxis in VWD Susan Halimeh Medical Thrombosis and Haemophilia treatment Center, Duisburg, Germany Dr. med. Susan Halimeh When is prophylaxis in patients with VWD recommended?
More informationAdvanced Heart Failure & Transplantation Fellowship Program
Advanced Heart Failure & Transplantation Fellowship Program Curriculum I. Patient Care When on the inpatient Heart Failure and Transplant Cardiology service, the cardiology fellow will hold primary responsibility
More informationManagement of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Recommendations of the European Society of Cardiology Updated version December 2002 Task Force on management
More informationNew Oral Anticoagulant Drugs What monitoring if any is required?
New Oral Anticoagulant Drugs What monitoring if any is required? Michelle Williamson Supervising Scientist High Throughput Haematology Pathology Queensland PAH Laboratory Overview Background What new oral
More informationUpdate on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
More informationCost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-analytic model
Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-analytic model Husam Abdel-Qadir MD, Idan Roifman MD, Harindra C. Wijeysundera
More information